Drug intelligence / Profile preview

SPY-007

Development stage: Preclinical
Lead developer: Spyre Therapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

SPY-007 is an investigational, long-acting monoclonal antibody designed to target both interleukin-17A (IL-17A) and interleukin-17F (IL-17F). Developed by Spyre Therapeutics, the biologic is engineered with half-life extension technology to enable infrequent subcutaneous dosing. SPY-007 is being developed primarily for the treatment of hidradenitis suppurativa (HS) as part of SPY-772, a co-formulated combination program that pairs SPY-007 with SPY-072, a long-acting anti-TL1A antibody.

Targets

IL-17A (Interleukin-17A)IL17F (Interleukin 17F)

Beyond the preview

Go deeper on SPY-007.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SPY-007.